News

Vogelmeier discusses major changes to the annual COPD report, including a broader threshold for escalating treatment after exacerbation.

Here, we spotlighted 4 late-breaker studies featured in our ACAAI 2025 coverage, along with 2 phase 3 trials.

After his sessions on TYK2 Inhibitors for psoriasis and on palmoplantar pustulosis, Vender discussed several key insights in this interview.

COPD is not a complex disease, Polverino explains. It's only complex to treat because of limited understanding.

In this Q&A, Soong discusses phase 2 results on povorcitinib, a JAK1 inhibitor that provides rapid relief from chronic spontaneous urticaria symptoms.

Benjamin Locksin speaks in this interview about his session titled ‘Encapsulating Progress With New and Emerging TYK2 Inhibitors for Psoriasis.’

Acoramidis also increased serum transthyretin in patients with wild-type ATTR-CM or the pathogenic variant ATTRv-CM.

FDA clears BrainsWay's Deep TMS for adolescents aged 15-21 years with major depressive disorder (MDD), expanding its use.

Polverino stresses the need for prospective analysis to validate CC16 and mucus plugs as viable biomarkers for COPD status.

Friedberg explains how an emphasis on physical fitness prior to and after surgery can significantly better long-term outcomes.

Friedberg discusses the inconsistent clinical pathways from disease progression to intervention in patients with a pair of highly deadly lung diseases.

Cohosts Stephen Greene, MD, and Muthiah Vaduganathan, MD, sat down with Ambarish Pandey, MD, to discuss the revolutionary POLY-HF trial and how polypills can fit into heart failure treatment.

Sands explains the potential benefits of obefazimod and reviews findings from ABTECT 1 and ABTECT 2 presented at ACG 2025.

This interview highlights long-term, phase 3 data from the SUNSHINE and SUNRISE core and extension trials on secukinumab for hidradenitis suppurativa.

Tumlin discussed improvements in UPCR and Gd-IgA1 seen with povetacicept.

At ACAAI 2025, Howell discussed sub-analytical data showing early itch and skin improvements with tapinarof cream in children with AD aged 2–17 years.

Late-breaking ACG 2025 data link rimegepant to increased rectal compliance and reduced rectal sensation in IBS without constipation.

Noureddin explains 24-week data showing significant MASH resolution, weight loss, and evidence of anti-fibrotic activity with the GLP-1/glucagon dual receptor agonist.

Lau discusses the importance of developing and applying technology to predict potential adverse cardiovascular outcomes in pregnant patients.

At ACAAI 2025, Adatia discussed interim KONFIDENT-KID trial findings showing oral sebetralstat safely reduced symptom burden in pediatric HAE.

Gatti highlights the role of social media in dermatology, noting its importance for business growth but emphasizing the need to focus on education.

Levy explains elafibranor’s role in the PBC 2LT treatment landscape and new long-term ELATIVE open-label extension data presented at AASLD 2025.

At ACAAI 2025, Harris spoke with HCPLive about Excellergy’s ECRI program, exploring IgE modulation, safety goals, and potential long-term effects in CSU.

ANTHEM-UC study findings presented at ACG show efficacy, durability and safety of icotrokinra in adults with moderate-to-severe ulcerative colitis.

Alkhouri breaks down recent therapeutic progress in MASH and explains new data on resmetirom’s use in patients with compensated MASH cirrhosis.

Discover groundbreaking insights from ASN Kidney Week on the SURPASS-CVOT trial.

Weir pointed out that significant benefits were seen with concurrent SGLT2 inhibitor use.

This discussion at the SDPA Fall Conference highlights some scheduling and contract essentials for early career success among physician associates (PAs).